Related Experiment Videos
Cancer therapy: switching off oncogenes.
Franca Pompetti1, Daniela Pilla, Raffaella Giancola
1Section on Molecular Biology, Laboratory of Haematology, Civil Hospital, Pescara-Italy.
Summary
In myc-induced tumors, inactivating the myc oncogene caused tumor regression and cell differentiation. Reactivating myc led to apoptosis, not tumor recurrence, suggesting a novel cancer therapy approach.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Cancer arises from genetic and epigenetic alterations allowing uncontrolled cell proliferation.
- The c-Myc oncogene plays a critical role in tumor development and progression.
Purpose of the Study:
- To investigate the consequences of c-Myc inactivation and reactivation in established myc-induced tumors.
- To explore the potential of targeting c-Myc for innovative cancer therapeutic strategies.
Main Methods:
- Induction of tumors using the myc oncogene in a preclinical model.
- Inactivation of the myc oncogene in existing tumors.
- Reactivation of the myc oncogene in tumor cells post-inactivation.
Main Results:
- Inactivation of the myc oncogene led to significant tumor regression.
- Tumor cells differentiated into mature osteocytes upon myc inactivation.
- Reactivation of myc in differentiated cells induced apoptosis, preventing tumor regrowth.
Conclusions:
- Targeting c-Myc by inactivation can reverse tumor growth and promote cell differentiation.
- Reactivating c-Myc after initial inactivation offers a potential strategy to eliminate residual cancer cells.
- These findings present a promising avenue for developing novel oncogene-targeted cancer therapies.